Remove Clinical Trials Remove Doctors Remove Genetics Remove Research
article thumbnail

Digital clinical trials: Trends to watch in 2023

Pharmaceutical Technology

Following the increased use of telemedicine during the Covid-19 pandemic, the potential of digital technologies in communication, data collection, and analysis has become increasingly realised by patients, healthcare systems, and clinical trial sponsors.

article thumbnail

Pancreatic Cancer Clinical Trials: Insights from PanCAN’s Senior Director

XTalks

Research is ongoing to find better ways to diagnose and treat pancreatic cancer. Please tell us more about your role as Senior Director, Clinical Trial Portfolio and Program Management at the Pancreatic Cancer Action Network. Another less common type is pancreatic neuroendocrine tumors (PNETs).

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Genetic biomarkers could personalise therapy for TNBC

Drug Discovery World

A new study has shed light on the genetic messages encoded by genes within ‘triple negative’ breast cancers (TNBC), and shows they could predict response to chemotherapy. The presence of these biomarkers could be used to accelerate the development of more personalised treatments for triple negative breast cancers.

article thumbnail

Why Black People Remain Underrepresented in Clinical Trials

XTalks

There has been increasing awareness around the need for improving inclusion and diversity in clinical trials. As such, there has been a growing emphasis on efforts to achieve better and more accurate representations of minority and underrepresented populations like Black people in clinical studies.

article thumbnail

Altura Partners with Michael J. Fox Foundation to Expand Diversity in Parkinson’s Research

ACRP blog

No cure or treatment to slow the progression has yet been found, but research is leading to deeper understanding of PD and its impact. However, this knowledge is hampered by underrepresentation of people of color and other underserved populations in Parkinson’s research studies. of the U.S.

article thumbnail

The NIH on accelerating research using diverse biomedical datasets

pharmaphorum

Martin Mendoza, PhD, director of health equity and health science policy for the All of Us Research Program at the National Institutes of Health (NIH), tells pharmaphorum about the programme and how it will accelerate research for the benefit of all patients. Gathering data.

article thumbnail

Personalising whole genome sequencing doubles diagnosis of rare diseases 

Drug Discovery World

A new study led by Medical Research Council-funded researchers from UCL has found that tailoring the analysis of whole genome sequencing to individual patients could double the diagnostic rates of rare diseases. . Dr Pitceathly continued: “In this study, every new genetic diagnosis had a direct impact on patient care.

Genome 52